Onconetix Files 10-K, Confirms Compliance as Smaller Reporting Company

TL;DR

**ONCO's 10-K confirms regulatory compliance, but without financials, it's a holding pattern for investors.**

AI Summary

Onconetix, Inc. reported its 10-K for the fiscal year ended December 31, 2024, indicating its status as a non-accelerated filer and a smaller reporting company. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., operates in the pharmaceutical preparations industry. Its common stock, with a $0.00001 par value, is traded on The Nasdaq Stock Market LLC under the ticker ONCO. The filing confirms that Onconetix has filed all required reports under the Securities Exchange Act of 1934 during the preceding 12 months and has submitted every Interactive Data File pursuant to Rule 405 of Regulation S-T. The company's business address is 201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202, and its telephone number is (513) 620-4101. Specific revenue and net income figures were not provided in the excerpt, but the company's operational compliance with SEC regulations was highlighted.

Why It Matters

This filing confirms Onconetix's continued compliance with SEC reporting requirements, which is crucial for investor confidence and market transparency. As a smaller reporting company, ONCO faces different regulatory burdens and investor scrutiny compared to larger pharmaceutical firms, impacting its competitive positioning. Employees and customers can infer a stable, compliant operational environment, though the lack of financial specifics in this excerpt limits deeper analysis. The broader market will note ONCO's adherence to filing standards, a baseline expectation for any publicly traded entity.

Risk Assessment

Risk Level: medium — The risk level is medium because while the company confirms compliance with SEC filings, the provided excerpt lacks crucial financial data such as revenue, net income, or cash flow. This absence prevents a comprehensive assessment of operational and financial health, leaving investors with incomplete information to evaluate the company's intrinsic value and future prospects.

Analyst Insight

Investors should await the full financial statements within the 10-K to assess Onconetix's performance and financial health. Without specific revenue, net income, or balance sheet figures, any investment decision would be speculative. Focus on the company's drug pipeline progress and cash burn once the complete filing is available.

Key Numbers

• $0.00001 — Common Stock Par Value (Indicates the nominal value per share of Onconetix's common stock.)
• 20241231 — Fiscal Year End Date (The period covered by this 10-K filing for Onconetix, Inc.)
• 001-41294 — Commission File Number (Unique identifier for Onconetix's filings with the SEC.)
• 20250602 — Filed As Of Date (The date Onconetix's 10-K was officially filed with the SEC.)

Key Players & Entities

• Onconetix, Inc. (company) — registrant for 10-K filing
• ONCO (company) — trading symbol on Nasdaq
• The Nasdaq Stock Market LLC (regulator) — exchange where ONCO common stock is registered
• Blue Water Biotech, Inc. (company) — former company name of Onconetix, Inc.
• Blue Water Vaccines Inc. (company) — former company name of Onconetix, Inc.
• SEC (regulator) — Securities and Exchange Commission
• December 31, 2024 (date) — fiscal year end for the 10-K
• 201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202 (company) — business address of Onconetix, Inc.
• $0.00001 (dollar_amount) — par value of common stock
• 513-620-4101 (person) — business phone number of Onconetix, Inc.

FAQ

Industry Context

Onconetix, Inc. operates within the pharmaceutical preparations industry, a sector characterized by extensive research and development, stringent regulatory oversight, and significant competition. Companies in this space often focus on developing novel therapeutics, which can involve long development cycles and substantial capital investment. Key trends include advancements in biotechnology, personalized medicine, and the ongoing demand for innovative treatments for various diseases.

Regulatory Implications

As a non-accelerated filer and smaller reporting company, Onconetix is subject to specific SEC reporting requirements. While these classifications allow for scaled disclosures, the company must still adhere to all filing obligations under the Securities Exchange Act of 1934, including timely submission of reports and interactive data files. Non-compliance could lead to penalties and affect investor confidence.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2024-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
• 2025-06-02: 10-K Filing Date — Indicates the official submission date of the annual report to the SEC.
• 2023-04-24: Name Change from Blue Water Biotech, Inc. — Reflects a significant corporate identity change.
• 2019-07-10: Name Change from Blue Water Vaccines Inc. — Indicates a prior corporate identity change.

Glossary

Non-accelerated filer

A filer that does not meet the thresholds for accelerated or large accelerated filer status, generally indicating a smaller market capitalization. (Onconetix's classification as a non-accelerated filer suggests its size and reporting requirements are less stringent.)

Smaller reporting company

A company that meets certain criteria for revenue and public float, allowing for scaled disclosure requirements. (This classification, along with non-accelerated filer status, indicates Onconetix is subject to reduced SEC reporting obligations.)

Par value

The nominal or face value of a share of stock, often a very small amount for common stock. (Onconetix's common stock has a par value of $0.00001, which is a nominal amount and not indicative of market value.)

Rule 405 of Regulation S-T

Requires registrants to submit all Interactive Data Files electronically. (Onconetix's confirmation of submitting these files indicates compliance with electronic filing mandates.)

SIC Code 2834

Standard Industrial Classification code for Pharmaceutical Preparations. (This code categorizes Onconetix's primary business activity within the pharmaceutical industry.)

Year-Over-Year Comparison

This 10-K filing covers the fiscal year ended December 31, 2024. As specific financial metrics such as revenue, net income, and margins were not detailed in the provided excerpt, a direct comparison to the previous year's filing cannot be made. However, the filing confirms Onconetix's compliance with SEC reporting requirements for the preceding 12 months, indicating continued operational adherence.

From the Filing

0001213900-25-049687.txt : 20250602 0001213900-25-049687.hdr.sgml : 20250602 20250602074107 ACCESSION NUMBER: 0001213900-25-049687 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 117 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250602 DATE AS OF CHANGE: 20250602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Onconetix, Inc. CENTRAL INDEX KEY: 0001782107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41294 FILM NUMBER: 251013155 BUSINESS ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 BUSINESS PHONE: 513-620-4101 MAIL ADDRESS: STREET 1: 201 E. FIFTH STREET STREET 2: SUITE 1900 CITY: CINCINNATI STATE: OH ZIP: 45202 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Biotech, Inc. DATE OF NAME CHANGE: 20230424 FORMER COMPANY: FORMER CONFORMED NAME: Blue Water Vaccines Inc. DATE OF NAME CHANGE: 20190710 10-K 1 ea0244122-10k_onconetix.htm ANNUAL REPORT     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-K   (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the fiscal year ended December 31 , 2024   OR   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the transition period from           to              Commission File Number: 001-41294   Onconetix, Inc. (Exact name of registrant as specified in its charter)   Delaware   81-2262816 (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)   201 E. Fifth Street , Suite 1900 Cincinnati , OH   45202 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: (513) 620-4101   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of exchange on which registered Common stock, $0.00001 par value   ONCO   The Nasdaq Stock Market LLC   Securities registered pursuant to Section 12(g) of the Act: None   Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒   Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒   Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐   Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.   Large accelerated filer ☐   Accelerated filer ☐ Non-accelerated filer   ☒   Smaller reporting company